Clinical trials
Completed Carcinoma, Ductal, Breast trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 3 |
| 2007 | 5 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 48 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GBG Forschungs GmbH | 4 |
| Case Comprehensive Cancer Center | 2 |
| City of Hope Medical Center | 2 |
| Radiation Therapy Oncology Group | 2 |
| ARCAGY/ GINECO GROUP | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| American College of Radiology Imaging Network | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Avelas Biosciences, Inc. | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Ductal, Breast | 48 |
| Breast Neoplasms | 37 |
| Carcinoma, Lobular | 16 |
| Carcinoma, Intraductal, Noninfiltrating | 13 |
| Breast Carcinoma In Situ | 10 |
| Inflammatory Breast Neoplasms | 8 |
| Breast Neoplasms, Male | 3 |
| Triple Negative Breast Neoplasms | 2 |
| Adenocarcinoma | 1 |
| Brain Neoplasms | 1 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.